Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Nov. 22, 2024 (HealthDay News) — For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure, according to a study published online Nov. 16 in the New England Journal of Medicine <\/em>to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.<\/p>\n Milton Packer, M.D., from the Baylor University Medical Center in Dallas, and colleagues conducted a double-blind, randomized trial involving 731 patients with heart failure, an ejection fraction of at least 50 percent, and a body mass index of at least 30 kg\/m2<\/sup>. Participants were randomly assigned to receive tirzepatide or placebo for at least 52 weeks (364 and 367 patients, respectively) and were followed for a median of 104 weeks.<\/p>\n The researchers found that adjudicated death from cardiovascular causes or a worsening heart failure event occurred in 9.9 and 15.3 percent of patients in the tirzepatide and placebo groups, respectively (hazard ratio, 0.62; 95 percent confidence interval, 0.41 to 0.95; P = 0.026). Worsening heart failure events occurred in 8.0 and 14.2 percent of patients in the tirzepatide and placebo groups, respectively (hazard ratio, 0.54; 95 percent confidence interval, 0.34 to 0.85); adjudicated death from cardiovascular causes occurred in 2.2 and 1.4 percent of patients, respectively (hazard ratio, 1.58; 95 percent confidence interval, 0.52 to 4.83).<\/p>\n “We observed a lower risk of a composite primary end point event with tirzepatide than with placebo over a median of two years,” the authors write. “This benefit was paralleled by an improvement in health status.”<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n